Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

NCT04132674 is registered in ClinicalTrials.gov with Vancouver Infectious Diseases Centre as lead sponsor.

NCT NCT04132674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04132674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
Lead sponsor
Vancouver Infectious Diseases Centre
Phase
Phase 4
Overall status
Unknown status
Start date
November 26, 2018
Completion date
December 31, 2020
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

drug use, human immunodeficiency virus i infection